Latest Market News

Echo IQ has completed a pivotal clinical validation of its EchoSolv HF software at the Mayo Clinic, achieving outstanding accuracy ahead of its FDA submission. This milestone sets the stage for potential US market entry into a $60 billion heart failure diagnostics sector.

Black Cat Syndicate announces a leadership transition with James Bruce appointed as Managing Director from April 2026, succeeding founder Gareth Solly who will remain as a Non-Executive Director.

DevEx Resources reports a major metallurgical breakthrough at its Kennedy Rare Earths Project in Queensland, achieving up to 68% recovery of critical magnet rare earth elements using a straightforward heap leach process with low acid consumption.

Altech Batteries has secured a strategic collaboration with a leading global battery manufacturer to evaluate its breakthrough Silumina Anodes™ silicon-enhanced technology, marking a significant step toward commercialisation.

Prodigy Gold reports strong gold intercepts from its 2025 drilling at the Tregony Deposit, setting the stage for an updated resource estimate and potential expansion in 2026.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for PYC-003, an RNA therapy targeting Polycystic Kidney Disease. This milestone moves the drug closer to pivotal Phase 2/3 trials.

Basin Energy has agreed to sell its Marshall Uranium Project to Green Canada Corporation, securing cash, shares, and a significant equity stake while retaining strategic rights and exposure to Canadian uranium assets.

Aeris Resources reported solid FY25 results within guidance and secured $80 million in new equity to fund exploration and development projects, positioning itself for significant growth in FY26.

Ryman Healthcare has completed a full refinancing of its $2 billion syndicated loan facilities, extending the average maturity to five years and enhancing funding flexibility. The move aligns with the company’s disciplined growth strategy and sets the stage for future capital management decisions.

The a2 Milk Company has secured key regulatory approvals in China, moving closer to launching its infant formula products under the a2MC brand by mid-2027.

Gentrack delivered solid FY25 results with 8% revenue growth and a doubling of net profit, driven by strong recurring revenues and strategic investments. The company is poised for accelerated expansion in FY26, backed by a maturing pipeline and new technology deployments.

Gentrack Group reported robust FY25 results with an 8% revenue rise to NZ$230.2m and a 119% jump in net profit, driven by strong growth in utilities and airports segments alongside strategic investments in its new cloud platform and global expansion.